Pharmacological and clinical development of a novel hypoglycemic agent: nateglinide

Nateglinide is a novel non-sulfonylurea antidiabetic agent by stimulating insulin secretion. Its action occurs rapidly and sustains shortly. It can effectively control mealtime glucose excursions and reduce the peak of postprandial hyperglycemia during single administration. It has synergistic effect with metformin for treating moderated or severe hyperglycemia. Nateglinide is safe and well tolerated with nearly no affects on the body weight of patients and rarely occurrence of hypoglycemia.